DNA assembly News
https://www.elegenbio.com/
Summary for https://www.elegenbio.com/: Elegen announces rapid clonal gene synthesis up to 15kb shipped as fast as 10 business days . Use ENFINIA DNA directly in synthetic biology workflows with minimal or no cloning and save weeks or months of time . Error rates as low as 1:70,000 bp (99.999 per base accuracy) ENFIIA does not require further purification through cloning and can be immediately used for mRNA synthesis by in vitro transcription. Elegen will help the builders in the next evolution of synthetic biology eliminate expensive, time-intensive and capital-intensive workflows.
https://www.genengnews.com/topics/genome-editing/enabling-the-synthetic-biology-revolution/
Summary for https://www.genengnews.com/topics/genome-editing/enabling-the-synthetic-biology-revolution/: ️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️
https://www.synbiobeta.com/read/oriciro-announces-series-b2-financing-to-advance-cell-free-dna-technology-for-innovative-therapeutics-and-synthetic-biology
Summary for https://www.synbiobeta.com/read/oriciro-announces-series-b2-financing-to-advance-cell-free-dna-technology-for-innovative-therapeutics-and-synthetic-biology: OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology . Asahi Kasei Medical Co., Ltd. invested in the company . The investment is expected to accelerate growth by leveraging expected synergies between both companies in the healthcare field . OriCiro Genomics announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology by June 6, 2022 . Company’s proprietary, world’s first cell-free cloning technology for large circular DNA for which conventional . PCR methods are not applicable . Asahi Kasei Medical , the third and first as a commercial enterprise . The investor will be able to predict the future of the next century . Mizuno is the latest company to announce a series of AI-free financing technologies to advance cell
https://www.synbiobeta.com/read/why-you-should-look-to-tokyo-for-the-cell-free-amplification-of-large-genome-scale-dna
Summary for https://www.synbiobeta.com/read/why-you-should-look-to-tokyo-for-the-cell-free-amplification-of-large-genome-scale-dna: Hirasaki: Cell-free DNA is one of the most important enabling technologies in synthetic biology . The company has achieved 1010-fold amplification from a single DNA molecule within 3 hours . OriCiro has joined a burgeoning synthetic biology startup landscape in Japan that includes the likes of Synplogen, BioPalette, and Spiber . Hirasaki says increasing the visibility of faster synthetic biology by introducing new products and services to the market . Japan will be increasingly recognized as a source of new synthetic biology . Tokyo-based Catur Genomics wants to introduce the increasing need for E-free technologies. The company will be presenting a new technology for cell-based cell cloning as a new technology for the future.
https://link.springer.com/article/10.1007/s11427-022-2252-0
Summary for https://link.springer.com/article/10.1007/s11427-022-2252-0: Xiao-Pang codec system is a preview of subscription content . Use the weekly Newsquiz to help with reading comprehension and vocabulary . Use this article to help people with reading comprehension and vocabulary . Use the weekly Newsquiz to test your knowledge of articles you need to share . Our imprints include BMC Palgrave Macmillan Apress .
https://synbioj.cip.com.cn/article/2023/2096-8280/2023-036.shtml
Summary for https://synbioj.cip.com.cn/article/2023/2096-8280/2023-036.shtml: ️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️️
